Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease
PHASE2CompletedINTERVENTIONAL
Enrollment
8
Participants
Timeline
Start Date
May 31, 2001
Study Completion Date
September 30, 2002
Conditions
Pompe DiseaseGlycogen Storage Disease Type IIAcid Maltase Deficiency DiseaseGlycogenosis 2
Interventions
DRUG
recombinant human acid alpha-glucosidase (rhGAA)
Trial Locations (1)
27710
Duke University Medical Center, Durham
All Listed Sponsors
lead
Genzyme, a Sanofi Company
INDUSTRY
NCT00025896 - Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease | Biotech Hunter | Biotech Hunter